Absorption of Cam-2445, an NK1 neurokinin receptor antagonist: In vivo, in situ, and in vitro evaluations

Journal of Pharmaceutical Sciences

Volumn 85, Issue 3, 1996, Pages 253-257

  Chan, O Helen ^a   Schmid, Heidi L ^a   Kuo, Be Sheng ^a   Wright, D Scott ^a   Howson, William ^b   Stewart, Barbra H ^a  

^a PFIZER INC   (United States)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA METHYL N (4 METHYLBENZYLOXYCARBONYL)TRYPTOPHAN ALPHA METHYLBENZYLAMIDE; CAM 2445; CAM 2689; N (3,4 DIMETHYLBENZYLOXYCARBONYL) ALPHA METHYLTRYPTOPHAN ALPHA METHYLBENZYLAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANXIETY; ARTHRITIS; ARTICLE; ASTHMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; HUMAN CELL; INTRADUODENAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIGRAINE; NONHUMAN; ORAL DRUG ADMINISTRATION; PORTAL VEIN BLOOD FLOW; PSYCHOSIS; RAT; VOMITING;

EID: 0029926022     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js9503338     Document Type: Article

References (20)

1. Guard, S.; Watson, S. P. Neurochem. Int. 1991, 18, 149-165.
2. Maggi, C. A.; Patacchini, R.; Rovero, P.; Giachetti, A. J. Anton. Pharmacol. 1993, 13, 23-93.
3. Nakanishi, S. Annu. Rev. Neurosci. 1991, 14, 123-136.
4. Pernow, B. Pharmacol. Rev. 1993, 55, 85-141.
5. Maggio, J. E. Annu. Rev. Neurosci. 1988. 11, 13-28.
6. Lowe, J. A., III; Snider, R. M. DN&P 1992, 5, 223-228.
7. Maggi, C. A.; Patacchini, R.; Rovero, P.; Giuliani, S.; Giachetti, A. Biochem. Soc. Trans. 1991, 19, 909-912.
8. Bountra, C.; Bunce, K.; Dale, T.; Gardner, C.; Jordan, C.; Twissell, D.; Ward, P. Eur. J. Pharamacol. 1993, 249, R3-R4.
9. Longmore, J.; Swain, C. J.; Hill, R. G. DN&P 1995, 8, 5-23.
10. Boyle, S.; Guard, S.; Higginbottom, M.; Horwell, D. C.; Howson, W.; McKnight, A. T.; Martin, K.; Pritchard, M. C.; O'Toole, J.; Raphy, J.; Rees, D. C.; Roberts, E.; Watling, K. J.; Woodruff, G. N.; Hughes, J. Bioorg. Med. Chem. 1994, 2, 357-370.
11. Stewart, B. H.; Chan, O. H.; Lu, R. H.; Reyner, E. L.; Schmid, H. L.; Hamilton, H. W.; Steinbaugh, B. A.; Taylor, M. D. Pharm. Res. 1995, 12, 693-699.
12. Tsuji, A.; Terasaki, T.; Tamai, I.; Hirooka, H. J. Pharmacol. Exp. Ther. 1987, 241, 594-601.
13. Hidalgo, I. J.; Hillgren, K M.; Grass, G. M.; Borchardt, R. T. Pharm. Res. 1991, 8, 222-227.
14. Ho, N. F. H.; Park, J. Y.; Ni, P. F.; Higuchi, W. I. In Animal Models for Oral Drug Delivery in Man: In Situ and In Vivo Approaches; Crouthamel, W.; Sarapu, A. C., Eds.; American Pharmaceutical Association: Washington, DC, 1983; pp 27-106.
15. Hu, M.; Sinko, P. J.; deMeere, A. L. J.; Johnson, D. A.; Amidon, G. L. J. theor. Biol. 1988, 131, 107-114.
16. Sinko, P. J. Pharm. Res. 1992, 9, 320-325.
17. Goldberg, D. M.; Campbell, R.; Roy, A. D. Biochim. Biophys. Acta 1968, 167, 613-615.
18. Riad. L. E.; Sawchuk, R. J. Pharm. Res. 1991, 8, 491-497.
19. Kaplan, S. A.; Jack, M. L. In Principles and Perspectives in Drug Bioavailability; Blanchard, J.; Sawchuk, R. J.; Brodie, B. B., Eds.; S. Karger: Basel, Switzerland, 1979; pp 156-191.
20. Barr, W. H.; Riegelman, S. J. Pharm. Sci. 1970, 53, 154-163.